A drug currently used to treat HIV has also been found to dramatically reduce the risk of infection, significantly more than the primary option available for pre-exposure prophylaxis or PrEP.
Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, including with Merck’s islatravir, experts said. Early lenacapavir ...
Results that may be inaccessible to you are currently showing.